Wealth Effects LLC Has $152,000 Position in SCYNEXIS, Inc. (NASDAQ:SCYX)

Wealth Effects LLC lessened its holdings in shares of SCYNEXIS, Inc. (NASDAQ:SCYX) by 8.5% in the third quarter, HoldingsChannel.com reports. The firm owned 102,000 shares of the company’s stock after selling 9,500 shares during the period. Wealth Effects LLC’s holdings in SCYNEXIS were worth $152,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of SCYX. Empowered Funds LLC grew its holdings in shares of SCYNEXIS by 8.1% during the first quarter. Empowered Funds LLC now owns 88,414 shares of the company’s stock valued at $130,000 after buying an additional 6,650 shares during the last quarter. AMH Equity Ltd lifted its position in SCYNEXIS by 19.9% in the 1st quarter. AMH Equity Ltd now owns 660,000 shares of the company’s stock valued at $970,000 after acquiring an additional 109,600 shares in the last quarter. Vanguard Group Inc. boosted its stake in SCYNEXIS by 8.3% during the 1st quarter. Vanguard Group Inc. now owns 1,687,670 shares of the company’s stock valued at $2,481,000 after purchasing an additional 129,153 shares during the last quarter. Finally, Acadian Asset Management LLC increased its holdings in SCYNEXIS by 5.4% during the 1st quarter. Acadian Asset Management LLC now owns 421,083 shares of the company’s stock worth $618,000 after purchasing an additional 21,700 shares in the last quarter. Institutional investors and hedge funds own 54.37% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut SCYNEXIS from a “hold” rating to a “sell” rating in a research report on Monday, August 12th.

SCYNEXIS Price Performance

NASDAQ SCYX opened at $1.52 on Tuesday. The company has a fifty day moving average price of $1.52 and a 200-day moving average price of $1.82. The firm has a market cap of $57.55 million, a price-to-earnings ratio of -2.11 and a beta of 1.50. SCYNEXIS, Inc. has a 1 year low of $1.26 and a 1 year high of $3.07.

SCYNEXIS (NASDAQ:SCYX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.11). SCYNEXIS had a negative return on equity of 57.41% and a negative net margin of 366.09%. The firm had revenue of $0.74 million during the quarter. On average, research analysts anticipate that SCYNEXIS, Inc. will post -0.68 EPS for the current fiscal year.

Insider Activity at SCYNEXIS

In other SCYNEXIS news, CEO Gonzalez David Angulo acquired 20,000 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were acquired at an average price of $1.37 per share, with a total value of $27,400.00. Following the completion of the transaction, the chief executive officer now owns 507,871 shares in the company, valued at approximately $695,783.27. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 2.85% of the stock is currently owned by company insiders.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.